That’s fake news. Real news COSTS. Please turn off your ad blocker for our web site.
Our PROMISE: Our ads will never cover up content.
Published: Tuesday, January 17, 2017 - 13:01 About a year ago, we shared with you our combination product review, Intercenter Consult Process Study Report, developed by the U.S. Food and Drug Administration’s (FDA) Office of Planning. The report findings were derived from focus group studies with reviewers from the FDA’s different centers and included input from industry. Since then, we have built on foundational policies and processes to address many of the issues identified in the report. Tremendous progress toward modernizing the combination products review program has been made by improving coordination, ensuring consistency, enhancing clarity, and providing transparency within the agency as well as with all stakeholders. We are excited to share our progress with you now. The table below summarizes some key achievements from the past year, including the publication of draft guidances, a variety of new processes, and a look at future goals. As technologies advance across multiple fields, the distinctions that previously allowed combination products to be neatly categorized by the FDA’s medical product centers are blurring or even vanishing. Combination products account for a growing proportion of products submitted for review, and the FDA will continue to collaborate on new approaches to ensure safe, effective, and innovative medical products are made available to patients as quickly as possible. Continued collaboration with you, our stakeholders, will be critical as together we continue to make progress in this important area. We are still listening and have much more work to do. Click here for larger view: Quality Digest does not charge readers for its content. We believe that industry news is important for you to do your job, and Quality Digest supports businesses of all types. However, someone has to pay for this content. And that’s where advertising comes in. Most people consider ads a nuisance, but they do serve a useful function besides allowing media companies to stay afloat. They keep you aware of new products and services relevant to your industry. All ads in Quality Digest apply directly to products and services that most of our readers need. You won’t see automobile or health supplement ads. So please consider turning off your ad blocker for our site. Thanks, Robert M. Califf, M.D., FDA’s Deputy Commissioner for Medical Products and Tobacco Nina L. Hunter, Ph.D., FDA’s Associate Director for Science Policy in the Office of Medical Products and TobaccoCombination Products Review Program
Progress and potential report
Our PROMISE: Quality Digest only displays static ads that never overlay or cover up content. They never get in your way. They are there for you to read, or not.
Quality Digest Discuss
About The Authors
Robert M. Califf
Nina L. Hunter
© 2023 Quality Digest. Copyright on content held by Quality Digest or by individual authors. Contact Quality Digest for reprint information.
“Quality Digest" is a trademark owned by Quality Circle Institute, Inc.